← Leaderboards
Anton Wellstein
Georgetown University
$12,396,274
Attributed
$22,135,022
Total exposure
17
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,135,022 · 17
By mechanism
P01$10,536,993 · 8
R01$8,236,679 · 4
T32$1,375,777 · 2
R33$1,150,703 · 1
R21$429,000 · 1
P50$405,870 · 1
Top collaborators
- Pedro A. Jose30 shared
- Kathryn L Sandberg30 shared
- William J Welch30 shared
- Christopher S Wilcox10 shared
- Michael B Atkins5 shared
- Patrick Alexander Forcelli4 shared
- Richard Schlegel3 shared
- Alexander Helmut Kurt Kroemer1 shared
Most similar at Georgetown University
Same institution · by research overlap
- Kathryn L Sandberg$21,619,723
- William J Welch$8,801,157
- Alexander Helmut Kurt Kroemer$3,077,112
Others in their field
Top investigators on “Oxidative Stress”
- Leonardo Trasande · New York University School Of Medicine$57,471,048
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$36,739,005
- Claire Gmachl · Princeton University$34,397,540
- Akram N Alshawabkeh · Northeastern University$31,872,089
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$31,629,832
- Robert O Wright · Brigham And Women'S Hospital$30,479,869
Research focus
Oxidative StressHypertensionGenesKidneyCellsInstructionProteinsResponseBlood PressurePathway InteractionsReceptorTissuesFibroblast Growth FactorBinding ProteinsIn VivoProgramsMessenger RnaSignal TransductionBlood VesselsBlood Pressure RegulationAdultExtracellularAngiotensin IiReactive Oxygen Species
Grant awards (72)
Cell-type-specific Evaluation of Liver Allografts during Normothermic-Machine-Perfusion$429,000
R21 · FY2025 · AI · contact PI
Pharmacological Sciences Training Program (PSTP)$321,270
T32 · FY2025 · GM
Pharmacological Sciences Training Program (PSTP)$329,616
T32 · FY2024 · GM
Pharmacological Sciences Training Program (PSTP)$318,321
T32 · FY2023 · GM
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$522,708
R01 · FY2022 · CA · contact PI
Pharmacological Sciences Training Program (PSTP)$156,108
T32 · FY2022 · GM
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,358
R01 · FY2021 · CA · contact PI
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,344
R01 · FY2020 · CA · contact PI
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$517,329
R01 · FY2019 · CA · contact PI
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors$533,211
R01 · FY2018 · CA · contact PI
Redox Regulation of Myogenic Responses$452,607
P01 · FY2017 · HL
D2R, via PON2 and DJ-1, Negatively Regulates Reactive Oxygen Species Production$409,108
P01 · FY2017 · HL
FGF Signaling and Oxidative Stress$323,326
P01 · FY2017 · HL · contact PI
Administrative Core$244,466
P01 · FY2017 · HL
Bioassay Core$220,605
P01 · FY2017 · HL
Animal Core$201,795
P01 · FY2017 · HL
D2R, via PON2 and DJ-1, Negatively Regulates Reactive Oxygen Species Production$494,934
P01 · FY2016 · HL
Redox Regulation of Myogenic Responses$376,892
P01 · FY2016 · HL
FGF Signaling and Oxidative Stress$293,753
P01 · FY2016 · HL · contact PI
Administrative Core$243,038
P01 · FY2016 · HL
Bioassay Core$227,693
P01 · FY2016 · HL
Animal Core$215,597
P01 · FY2016 · HL
D2R, via PON2 and DJ-1, Negatively Regulates Reactive Oxygen Species Production$490,303
P01 · FY2015 · HL
Conditionally reprogrammed cells as a novel tool for biobanking$378,782
R33 · FY2015 · CA
Redox Regulation of Myogenic Responses$372,261
P01 · FY2015 · HL
FGF Signaling and Oxidative Stress$289,122
P01 · FY2015 · HL · contact PI
Administrative Core$238,409
P01 · FY2015 · HL
Bioassay Core$223,064
P01 · FY2015 · HL
Animal Core$210,968
P01 · FY2015 · HL
D2R, via PON2 and DJ-1, Negatively Regulates Reactive Oxygen Species Production$505,319
P01 · FY2014 · HL
Redox Regulation of Myogenic Responses$376,783
P01 · FY2014 · HL
Conditionally reprogrammed cells as a novel tool for biobanking$371,415
R33 · FY2014 · CA
FGF Signaling and Oxidative Stress$286,255
P01 · FY2014 · HL · contact PI
Administrative Core$231,033
P01 · FY2014 · HL
Bioassay Core$214,324
P01 · FY2014 · HL
Animal Core$201,154
P01 · FY2014 · HL
Redox Regulation of Myogenic Responses$456,091
P01 · FY2013 · HL
D2R, via PON2 and DJ-1, Negatively Regulates Reactive Oxygen Species Production$409,108
P01 · FY2013 · HL
Conditionally reprogrammed cells as a novel tool for biobanking$400,506
R33 · FY2013 · CA
FGF Signaling and Oxidative Stress$325,816
P01 · FY2013 · HL · contact PI
Administrative Core$246,348
P01 · FY2013 · HL
Bioassay Core$222,303
P01 · FY2013 · HL
Animal Core$203,348
P01 · FY2013 · HL
Oxidative Stress, Hypertension and an FGF-binding protein$334,658
P01 · FY2011 · HL · contact PI
Oxidative Stress, Hypertension and an FGF-binding protein$334,658
P01 · FY2010 · HL · contact PI
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$280,788
R01 · FY2010 · CA · contact PI
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$280,788
R01 · FY2009 · CA · contact PI
Oxidative Stress, Hypertension and an FGF-binding Protein$327,196
P01 · FY2008 · HL · contact PI
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$280,788
R01 · FY2008 · CA · contact PI
Oxidative Stress, Hypertension and an FGF-binding Protein$334,658
P01 · FY2007 · HL · contact PI
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$280,788
R01 · FY2007 · CA · contact PI
Pancreas Cancer Specialized Program of Research Excelle*$209,700
R01 · FY2007 · CA · contact PI
Inhibition of the ALK Receptor Kinase$412,421
R01 · FY2006 · CA · contact PI
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$289,173
R01 · FY2006 · CA · contact PI
Pancreas Cancer Specialized Program of Research Excelle*$215,963
R01 · FY2006 · CA · contact PI
Clinical Pharmacology Training Grant$123,734
T32 · FY2006 · GM · contact PI
Inhibition of the ALK Receptor Kinase$410,175
R01 · FY2005 · CA
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$296,595
R01 · FY2005 · CA
Pancreas Cancer Specialized Program of Research Excelle*$221,160
R01 · FY2005 · CA
Clinical Pharmacology Training Grant$3,094
T32 · FY2005 · GM
Inhibition of the ALK Receptor Kinase$398,357
R01 · FY2004 · CA
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$296,595
R01 · FY2004 · CA
Pancreas Cancer Specialized Program of Research Excelle*$221,160
R01 · FY2004 · CA
CLINICAL PHARMACOLOGY TRAINING GRANT$123,634
T32 · FY2004 · GM
Inhibition of the ALK Receptor Kinase$391,333
R01 · FY2003 · CA
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$296,595
R01 · FY2003 · CA
Pancreas Cancer Specialized Prog of Research Excellence$221,160
R01 · FY2003 · CA
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$296,595
R01 · FY2002 · CA
MAMMARY CARCINOGENESIS--THE ROLE OF PLEIOTROPHIN$135,290
P50 · FY2002 · CA
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF$296,595
R01 · FY2001 · CA
MAMMARY CARCINOGENESIS--THE ROLE OF PLEIOTROPHIN$135,290
P50 · FY2001 · CA
MAMMARY CARCINOGENESIS--THE ROLE OF PLEIOTROPHIN$135,290
P50 · FY2000 · CA